BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011) NSCLC Interim Analysis BA3011 Monotherapy 1.8 mg/kg Q2W bicatla 02 4 6 8 10 12 14 16 18 20 22 Weeks Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. 24 Data Cut Date: 30Jun23 26 28 30 1 32 Partial Response Stable Disease Progressive Disease Ongoing response AXL TmPS = 1% Patient featured in next slide Voluntary patient withdrawal Withdrawal due to AE Scan date 34 36 38 40 42 BioAtla| Overview 35

View entire presentation